Why VBI Vaccines Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket

7/6/23 8:03:56 AM ET

Engineering & Construction

Consumer Discretionary

Medical Specialities

Health Care

Get the next $ADD alert in real time by email

Gainers

Akumin Inc. (NASDAQ:AKU) shares surged 58.2% to $0.2865 in pre-market trading. Akumin recently named Krishna Kumar as President and Chief Operating Officer of the Company.
Mullen Automotive, Inc. (NASDAQ:MULN) shares gained 52.8% to $0.2612 in pre-market trading. Mullen Automotive shares jumped 69% on Wednesday after the company announced the retention of a law group to investigate possible naked short selling.
Micromobility.com Inc. (NASDAQ:MCOM) shares rose 19.8% to $0.1354 in pre-market trading. micromobility.com recently announced a strategic realignment to strengthen its financial position and drive profitability.
Caravelle International Group (NASDAQ:CACO) rose 19.6% to $0.6399 in pre-market trading.
AIM ImmunoTech Inc. (NYSE:AIM) gained 18.3% to $0.7690 in pre-market trading after declining 3% on Wednesday.
Histogen Inc. (NASDAQ:HSTO) rose 18% to $0.8563 in pre-market trading. Histogen announced its decision to pause further development of its programs and commence a process to explore strategic alternatives.
IGC Pharma, Inc. (NYSE:IGC) shares rose 14.7% to $0.39 in pre-market trading after gaining around 5% on Wednesday.
IronNet, Inc. (NYSE:IRNT) shares climbed 13.9% to $0.2392 in pre-market trading after gaining 6% on Wednesday.
Avalo Therapeutics, Inc. (NASDAQ:AVTX) shares gained 11.8% to $0.4025 in pre-market trading. Avalo Therapeutics recently said its Phase 2 Peak trial for quisovalimab In patients with non-eosinophilic asthma missed its primary endpoint.
Aurora Mobile Limited (NASDAQ:JG) gained 7.2% to $0.3112 in pre-market trading. Aurora Mobile secured approval to transfer to Nasdaq Capital Market.

Losers

Allarity Therapeutics, Inc. (NASDAQ:ALLR) fell 26.9% to $6.05 in pre-market trading. Allarity Therapeutics shares jumped 31% on Wednesday after the company said the initial data from Phase 2 trial of Ixempra shows potential for improved clinical benefit in DRP-selected metastatic breast cancer patients.
VBI Vaccines Inc. (NASDAQ:VBIV) fell 23.5% to $1.85 in pre-market. VBI Vaccines and Brii Biosciences announced the expansion of their hepatitis B partnership. The company also reported proposed concurrent public offering and registered direct offering of common shares and warrants.
Tattooed Chef, Inc. (NASDAQ:TTCF) fell 18.7% to $0.2334 in pre-market trading. Tattooed Chef recently announced it intends to file for voluntary Chapter 11 Bankruptcy protection.
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) fell 16.8% to $0.2069 in pre-market trading after the company received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month extension period granted by Nasdaq, and hence the company's shares will be suspended from trading on NASDAQ at the open of business on July 7, 2023.
Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) shares dropped 14.3% to $0.5001 in pre-market trading after gaining over 12% on Wednesday.
Senti Biosciences, Inc. (NASDAQ:SNTI) fell 12.3% to $0.5910 in pre-market trading after adding over 5% on Wednesday.
Guardion Health Sciences, Inc. (NASDAQ:GHSI) shares fell 12.2% to $7.00 in pre-market trading. Guardion Health Sciences recently named Jan Hall as President and Chief Executive Officer.
Calliditas Therapeutics AB (NASDAQ:CALT) fell 11.2% to $15.80 in pre-market trading after gaining around 13% on Wednesday.
Color Star Technology Co., Ltd. (NASDAQ:ADD) fell 10.7% to $1.20 in pre-market trading. Color Star Technology recently said that its subsidiary, Color Metaverse Pte. Ltd, has entered into a strategic cooperation framework agreement with Beijing Zhong Guang Shi Xun International Cultural Development Co., Ltd. in order to further develop its business in the Asia live events market in the future.
Greenbrook TMS Inc. (NASDAQ:GBNH) shares dropped 10.1% to $0.6205 in pre-market trading. Greenbrook TMS recently reported the acceptance of Mr. Benjamin Klein's resignation from the board of directors of the Company.

Now Read This: Investor Optimism Improves Slightly Following Fed Minutes

Get the next $ADD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ADD
$AKU
$ALLR
$AVTX

Company	Date	Price Target	Rating	Analyst
Avalo Therapeutics Inc. $AVTX	10/24/2024		Neutral	H.C. Wainwright
Avalo Therapeutics Inc. $AVTX	4/16/2024	$35.00	Perform → Outperform	Oppenheimer
Aurora Mobile Limited $JG	3/12/2024	$7.00	Neutral → Buy	Alliance Global Partners
Calliditas Therapeutics AB $CALT	6/20/2023	$60.00	Buy	H.C. Wainwright
Calliditas Therapeutics AB $CALT	3/1/2023	$18.00	Neutral	Guggenheim
Akumin Inc. $AKU	11/14/2022	$3.50 → $3.00	Buy → Speculative Buy	Canaccord Genuity
VBI Vaccines Inc. New $VBIV	11/11/2022	$5.00 → $2.00	Strong Buy → Outperform	Raymond James
Tattooed Chef Inc $TTCF	10/24/2022	$10.00 → $4.50	Outperform → Market Perform	Cowen

More analyst ratings

$ADD
$AKU
$ALLR
$AVTX
Press Releases

Fastest customizable press release news feed in the world

Mullen Ramping Up for Start of US Battery Production
Anticipated start of production to begin in mid-2025 To date, Mullen has installed three battery lines at its Fullerton facility and planned for an additional two lines High volume standard battery chemistry lineHigh precision, low volume standard chemistry R&D lineA high precision, low volume solid-state polymer R&D lineAn additional high volume standard chemistry battery line is anticipated to be installed in December 2024An additional high volume, fully automated wire bonding line to be installed by February 2025 for use with multiple chemistries BREA, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- via IBN -- Mullen Automotive, Inc. (NASDAQ:MULN) ("Mullen" or the "Company"), an electric
11/21/24 9:15:00 AM ET
$MULN
EDP Services
Technology
Color Star Technology Received Nasdaq Notification Letter Regarding Bid Price Deficiency
NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Color Star Technology Co., Ltd. (NASDAQ:ADD) ("Color Star" or the "Company"), an entertainment technology company with a global network that focuses on the application of technology and artificial intelligence in the entertainment industry, announced today that on November 14, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that the minimum bid price per share for its Class A ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set f
11/20/24 4:05:00 PM ET
$ADD
Engineering & Construction
Consumer Discretionary
Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change to the AIM Board
The Delaware Supreme Court Ruled that the Incumbent Board Breached its Fiduciary Duties to Stockholders AIM Board Wasted Millions in Furtherance of Improper Purpose Stockholders Urged to Act Now Before the Board's Self-Interested Behavior Irreversibly Damages the Company Stockholders Should Not be Fooled by Misleading Statements by AIM Board – The Facts Speak for Themselves Kellner Group Nominees Bring Skills, Experience and Credibility Necessary for AIM to be Successful NEW YORK, Nov. 14, 2024 /PRNewswire/ -- Ted Kellner, as the nominating stockholder and a nominee, together with his other nominees, Todd Deutsch, Robert L. Chioini and Paul W. Sweeney (collectively, the "Kellner Group," "we"
11/20/24 11:50:00 AM ET
$AIM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$ADD
$AKU
$ALLR
$AVTX
Financials

Live finance-specific insights

AIM ImmunoTech Reports Third Quarter 2024 Financial Results and Provides Corporate Update
– Continued execution across Ampligen® clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space – Driving significant momentum with positive clinical trial data, underscoring big pharma collaboration and commercialization opportunities – Company to host conference call and webcast today, November 15th, at 8:30 AM ET OCALA, Fla., Nov. 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") has reported its financial results for the third quarter 2024. As previously announced, the Company will host a conference call and webcast today, November 15, 2024 at 8:30 AM ET (details below). AIM Chief Execu
11/15/24 7:29:00 AM ET
$AIM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the third quarter of 2024 and provided a summary of recent pipeline and corporate highlights. "Over the past quarter, we have continued to execute on our clinical milestones and look forward to sharing initial results from the clinical trial of SENTI-202 before 2024 year-end," said Timothy Lu, MD, PhD, Chief Executive Officer and Co-Founder of Senti Bio. "As we look toward 2025, we anticipate sharing add
11/14/24 4:05:00 PM ET
$SNTI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline
POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ("IGC" or the "Company") (NYSE:IGC) today announced its financial results and strategic advancements for the second fiscal quarter of 2025 ended September30, 2024. The quarter was marked by significant progress in the Company's pipeline, particularly in the development of potential treatments for Alzheimer's and other neurological and metabolic disorders. IGC Pharma, Inc. Q2 FY2025 Company's HighlightsCrossing the Blood-Brain Barrier with TGR-63: July 9, 2024 - Preclinical analyses for TGR-63 demonstrated this compound's ability to cross the blood-brain barrier with a favorable safety profile, positioning it for further therap
11/14/24 8:30:00 AM ET
$IGC
Biotechnology: Pharmaceutical Preparations
Health Care

$ADD
$AKU
$ALLR
$AVTX
Leadership Updates

Live Leadership Updates

Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, today reported financial results for the third quarter ended September 30, 2024, and provided an update on recent operational highlights. "This quarter's progress marks a steady period of advancement for Allarity as we have maintained a strong cash position, achieved record patient duratio
11/14/24 8:00:00 AM ET
$ALLR
Biotechnology: Pharmaceutical Preparations
Health Care
AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders
Warns Shareholders that Activist Group's Self-Interested Agenda Could Disrupt AIM's Momentum and Destroy Chances for Near-Term Value Creation Expresses Excitement About Encouraging Progress of Clinical Trials for Ampligen in High-Value Indications Including Pancreatic Cancer Urges Shareholders to Safeguard AIM by Voting "FOR" ALL Four of the Board's Incumbent Candidates and Discarding Any Proxy Materials from the Activist Group Visit www.SafeguardAIM.com for More Information AIM ImmunoTech Inc. (NYSE:AIM) (the "Company") today announced that the Company has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its upcoming 2024 Annual M
11/4/24 8:00:00 AM ET
$AIM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
- Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors - Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu
11/4/24 7:30:00 AM ET
$ATNM
$AVTX
$RDHL
$TENX
Biotechnology: Pharmaceutical Preparations
Health Care

$ADD
$AKU
$ALLR
$AVTX
Market Insights

Live Market Insights

Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of General Dynamics Corporation (NYSE:GD) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter EPS results. Revenue for the quarter increased 18% year-over-year to $11.976 billion, beating the consensus of $11.438 billion. EPS of $3.26 (up 20.7% YoY) missed the consensus of $3.29, according to data from Benzinga Pro. General Dynamics shares declined 5.2% to $279.26 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers NuZee, Inc. (NASDAQ:NUZE) jumped 192% to $3.01. Dermata Therapeutics, Inc. (NASDAQ:DRMA) rose 142.4% to $3.0799 after falling over 22% on Tuesday. Selina Hospitality PLC
7/24/24 1:26:11 PM ET
$ALGM
$ALKS
$ALLR
$ATCH
Semiconductors
Technology
Biotechnology: Pharmaceutical Preparations
Health Care
What's Going On With Mullen Automotive Stock Today?
Mullen Automotive, Inc. (NASDAQ:MULN) shares are trading lower on Wednesday. According to Benzinga Pro, MULN stock has lost over 98% in the past year. Today, Mullen has announced that GAMA, one of its international distributors, has placed an order for 29 units of the Mullen GO, the company’s commercial micro urban delivery vehicle. The order, valued at $304,000 is scheduled for shipment to GAMA in early August 2024. Recently, Mullen appointed GAMA as its European distribution partner for southeastern Europe, encompassing the Balkans Region. Related: Mullen Automotive Hires New Distributor In Europe – What’s Going On? This includes Bosnia and Herzegovina, Serbia, Montenegro
7/24/24 12:27:29 PM ET
$MULN
EDP Services
Technology
AIM ImmunoTech Announces New Pre-Clinical Data Showing Ampligen As Part Of Combination Therapy Slows Melanoma Tumor Growth And Improves Survival In Mouse Model
7/24/24 8:50:35 AM ET
$AIM
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care